CVS Health (CVS) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for CVS Health (NYSE: CVS):

  • 2/9/2018 – CVS Health was given a new $85.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 2/9/2018 – CVS Health had its price target lowered by analysts at Robert W. Baird from $85.00 to $80.00. They now have a “neutral” rating on the stock.
  • 2/9/2018 – CVS Health was given a new $98.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 2/8/2018 – CVS Health was given a new $89.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 2/2/2018 – CVS Health was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 1/30/2018 – CVS Health was upgraded by analysts at Needham & Company LLC from a “buy” rating to a “strong-buy” rating. They now have a $100.00 price target on the stock, up previously from $88.00.
  • 1/24/2018 – CVS Health was given a new $95.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 1/18/2018 – CVS Health had its “outperform” rating reaffirmed by analysts at Cowen Inc. They now have a $99.00 price target on the stock, up previously from $81.00.
  • 1/16/2018 – CVS Health was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $76.66 price target on the stock.
  • 1/8/2018 – CVS Health had its price target raised by analysts at Leerink Swann from $82.00 to $90.00. They now have an “outperform” rating on the stock.
  • 1/5/2018 – CVS Health had its price target raised by analysts at SunTrust Banks, Inc. to $90.00. They now have a “buy” rating on the stock.
  • 1/5/2018 – CVS Health was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $88.00 price target on the stock.
  • 1/4/2018 – CVS Health was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $77.11 price target on the stock.
  • 1/4/2018 – CVS Health was upgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “strong-buy” rating. They now have a $90.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/4/2018 – CVS Health was upgraded by analysts at UBS Group AG from an “outperform” rating to a “strong-buy” rating.
  • 1/2/2018 – CVS Health had its price target raised by analysts at Needham & Company LLC from $85.00 to $88.00. They now have a “buy” rating on the stock.
  • 12/31/2017 – CVS Health was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 12/26/2017 – CVS Health had its “buy” rating reaffirmed by analysts at Tigress Financial.

Shares of CVS Health Corp (CVS) opened at $69.39 on Monday. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $70,462.84, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 1.16 and a beta of 0.93. CVS Health Corp has a 1 year low of $66.45 and a 1 year high of $84.00.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.88 by $0.04. The business had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. CVS Health’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.71 EPS. equities research analysts predict that CVS Health Corp will post 6.47 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th were given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date was Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 30.91%.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.61% of the company’s stock.

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply